The preliminary results show an ORR of 40% of patients with HER2-low, ER− breast cancer, ORR of 33% among patients with HER2+ breast cancer, and ORR of 28% among patients with HER2-low, HR+ breast cancer [55]. Here, ERBB2 is linked to breast carcinoma.